Our Insights Chronic Disease Anthony Iannacci 3/4/24 Chronic Disease Anthony Iannacci 3/4/24 Monoclonal antibodies for Alzheimer’s disease: questionable clinical benefit at a high price Read More Chronic Disease Anthony Iannacci 8/29/23 Chronic Disease Anthony Iannacci 8/29/23 Evrysdi: A Potential Game-Changer for SMA Type 1 Patients Read More Want to get in touch? Click here
Chronic Disease Anthony Iannacci 3/4/24 Chronic Disease Anthony Iannacci 3/4/24 Monoclonal antibodies for Alzheimer’s disease: questionable clinical benefit at a high price Read More
Chronic Disease Anthony Iannacci 8/29/23 Chronic Disease Anthony Iannacci 8/29/23 Evrysdi: A Potential Game-Changer for SMA Type 1 Patients Read More
